TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex

Chen Luo; Rongfa Yuan; Leifeng Chen; Wei Zhou; Wei Shen; Yumin Qiu; Jun Shao; Jinlong Yan; Jianghua Shao

doi:10.18632/oncotarget.22497

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex

Chen Luo, Rongfa Yuan, Leifeng Chen, Wei Zhou, Wei Shen, Yumin Qiu, Jun Shao, Jinlong Yan and Jianghua Shao _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:106565-106576. https://doi.org/10.18632/oncotarget.22497

Metrics: PDF 1628 views | HTML 2102 views | ?

Abstract

Chen Luo1,2,*, Rongfa Yuan1,2,*, Leifeng Chen1,2, Wei Zhou3, Wei Shen1, Yumin Qiu1,2, Jun Shao1,2, Jinlong Yan1,2 and Jianghua Shao1,2

1Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

2Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang 330006, China

3Department of Gastrointestinal Surgery, Jiangxi Provincial Cancer Hospital, Nanchang 330029, China

*These authors contributed equally to this work

Correspondence to:

Jianghua Shao, email: [email protected]

Keywords: TAB3; Survivin; NF-κB pathway; colorectal cancer; metastasis

Received: August 02, 2017 Accepted: October 28, 2017 Published: November 18, 2017

ABSTRACT

Transforming growth factor-β-activated kinase 1 (TAK1)-binding protein 3 (TAB3) is involved in cancer proliferation and metastasis, but its role in colorectal cancer remains unclear. In this study, we demonstrated that TAB3 is upregulated in colorectal cancer tissues and that high TAB3 levels correlated with tumor metastasis and a poor prognosis in colorectal cancer. In addition, TAB3 knockdown decreased Survivin expression and suppressed colorectal cancer cell migration and invasion in vitro, and reduced liver metastasis in vivo. Importantly, we found that TAB3 regulated Survivin expression by activating the NF-κB pathway through the formation of the TAK1-TAB3-TRAF6 complex. These findings suggest TAB3 may be a useful prognostic biomarker in colorectal cancer and a target for treatment of metastatic colorectal cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22497

Publication Alerts

Research Papers:

TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex

Abstract